PURPOSE: Recently, the safety profile of local anaesthetics in intra-articular use became into focus of investigation. Opioid drugs have a different mode of action and may be a safe and potent alternative for intra-articular application. The purpose of this in vitro study is to provide evidence for significant chondrotoxicity of amide-type local anaesthetics even after short-term application on human chondrocytes and to demonstrate the absence of such negative effects for opioids [morphine, morphine-6-glucuronide (M6G)]. METHOD: Visually intact cartilage explants of human, mainly osteoarthritic joints (n = 9), were harvested and cultivated in monolayer for expansion and transferred into alginate bead. The beads were incubated for increasing incubation times (15 min, 1 and 4 h) in decreasing concentrations (full, ½, ¼ for 15 min) of bupivacaine, ropivacaine, morphine, M6G or saline control. Adenosine triphosphate content of 798 beads was measured 3 days post-incubation to assess cell viability. RESULTS: A clear ranking of cytotoxic potency: bupivacaine > ropivacaine > morphine = M6G = saline was observed. Results reveal a dose- and time-dependent manner of cytotoxic effects on human chondrocytes for bupivacaine and ropivacaine but not for opioids. Cell viability after exposure to morphine and M6G was comparable to exposure to saline. CONCLUSION: The results confirm dose- and time-dependent cytotoxic effects on human chondrocytes for amide-type local anaesthetics. This study confirms the safety of morphine and M6G in terms of an absence of cytotoxic effects after intra-articular application, making them safe potential alternatives in clinical practice.
PURPOSE: Recently, the safety profile of local anaesthetics in intra-articular use became into focus of investigation. Opioid drugs have a different mode of action and may be a safe and potent alternative for intra-articular application. The purpose of this in vitro study is to provide evidence for significant chondrotoxicity of amide-type local anaesthetics even after short-term application on human chondrocytes and to demonstrate the absence of such negative effects for opioids [morphine, morphine-6-glucuronide (M6G)]. METHOD: Visually intact cartilage explants of human, mainly osteoarthritic joints (n = 9), were harvested and cultivated in monolayer for expansion and transferred into alginate bead. The beads were incubated for increasing incubation times (15 min, 1 and 4 h) in decreasing concentrations (full, ½, ¼ for 15 min) of bupivacaine, ropivacaine, morphine, M6G or saline control. Adenosine triphosphate content of 798 beads was measured 3 days post-incubation to assess cell viability. RESULTS: A clear ranking of cytotoxic potency: bupivacaine > ropivacaine > morphine = M6G = saline was observed. Results reveal a dose- and time-dependent manner of cytotoxic effects on human chondrocytes for bupivacaine and ropivacaine but not for opioids. Cell viability after exposure to morphine and M6G was comparable to exposure to saline. CONCLUSION: The results confirm dose- and time-dependent cytotoxic effects on human chondrocytes for amide-type local anaesthetics. This study confirms the safety of morphine and M6G in terms of an absence of cytotoxic effects after intra-articular application, making them safe potential alternatives in clinical practice.
Authors: Ian K Y Lo; Paul Sciore; May Chung; Sherri Liang; Richard B Boorman; Gail M Thornton; Jerome B Rattner; Kenneth Muldrew Journal: Arthroscopy Date: 2009-07 Impact factor: 4.772
Authors: Andreas H Gomoll; Adam B Yanke; Richard W Kang; Susan Chubinskaya; James M Williams; Bernard R Bach; Brian J Cole Journal: Am J Sports Med Date: 2008-10-02 Impact factor: 6.202
Authors: Alan Anz; Matthew J Smith; Aaron Stoker; Cole Linville; Heather Markway; Keith Branson; James L Cook Journal: Arthroscopy Date: 2009-01-24 Impact factor: 4.772
Authors: Benjamin Jacob; Timo Zippelius; Nadja Kloss; Kathrin Benad; Christiane Schwerdt; Paula Hoff; Georg Matziolis; Eric Röhner Journal: Cartilage Date: 2018-02-22 Impact factor: 4.634
Authors: Jannis Bodden; Gabby B Joseph; Silvia Schirò; John A Lynch; Nancy E Lane; Charles E McCulloch; Michael C Nevitt; Thomas M Link Journal: Arthritis Res Ther Date: 2021-05-22 Impact factor: 5.156
Authors: Monika Herten; Theodosios Bisdas; Dennis Knaack; Karsten Becker; Nani Osada; Giovanni B Torsello; Evgeny A Idelevich Journal: Front Microbiol Date: 2017-12-05 Impact factor: 5.640
Authors: Monika Herten; Evgeny A Idelevich; Sonja Sielker; Karsten Becker; Anna S Scherzinger; Nani Osada; Giovanni B Torsello; Theodosios Bisdas Journal: Med Sci Monit Basic Res Date: 2017-06-27
Authors: Travis Farmer; S Craig Morris; Robert Quigley; Nirav H Amin; Montri D Wongworawat; Hasan M Syed Journal: Adv Pharmacol Pharm Sci Date: 2020-01-04